Prof. Dr. Huachuan Zheng | Pharmacology | Best Innovation Award
The First Affiliated Hospital of Jinzhou Medical University | China
Prof. Dr. Huachuan Zheng is a distinguished scholar, educator, and research leader whose pioneering work in oncology has significantly advanced the understanding of cancer biology and its clinical applications. With a strong academic foundation that began at China Medical University, where he earned his B.M., M.S., and M.D. degrees, followed by a Ph.D. in Pathology from the University of Toyama in Japan, Prof. Zheng has built a career dedicated to unraveling the molecular mechanisms underlying tumor development and progression. His postdoctoral fellowship at the Kanagawa Cancer Center in Japan further strengthened his expertise in cancer molecular pathology, setting the stage for a prolific academic and research journey.Throughout his career, Prof. Zheng has held several prestigious positions, including serving as the Director of Basic and Translational Cancer Laboratories, Central Laboratories, Experimental Animal Centers, and Cancer Experiment Centers at leading institutions such as the First Affiliated Hospital of Jinzhou Medical University and the Affiliated Hospital of Chengde Medical University. His leadership has extended beyond research to academic administration, where he has contributed as Secretary of the Party Committee and Executive Vice Dean at the Jinzhou Medical University Academy of Life Sciences. Currently, he serves as Director, Professor, and Doctoral Supervisor at the First Affiliated Hospital of Jinzhou Medical University, where he continues to guide innovative cancer research and mentor the next generation of scientists. Prof. Zheng’s research has focused on critical areas such as the molecular mechanisms driving malignant tumor initiation and metastasis, the carcinogenic pathways involving JC virus T antigen, cancer bioinformatics, and the development of spontaneous tumor transgenic animal models. Prof. Zheng leads cutting-edge research on malignant tumor initiation, metastasis, JC virus oncogenesis, cancer bioinformatics, and transgenic animal models. His prolific output includes 212 documents, 5,182 citations, and an h-index of 36, reflecting his global impact on cancer research and precision oncology. His groundbreaking work has not only contributed to the fundamental understanding of cancer biology but has also paved the way for translational applications in early diagnosis, targeted therapy, and personalized treatment approaches for various malignancies, including lung, digestive system, and gynecological cancers.
Profile: Scopus
Featured Publications
Author(s). (2025). RNF180 suppressed aggressiveness by degrading NOTCH1, TRIM24 and FOXC1, and chemoresistance by degrading ACC1 and ACLY in colorectal cancer. International Immunopharmacology.
Author(s). (2025). Effective synthesis of benzodiazepine sulfonamide-based MGAT2 inhibitors and evaluation of their antitumor activity. RSC Advances.
Author(s). (2025). Dkk3 inhibits the aggressiveness and mitigates chemoresistance through low lipid droplet formation in gastric cancer: A biomarker and gene therapy target. International Immunopharmacology.
Author(s). (2025). IFN-γ downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells. Cancer Biology and Therapy.
Author(s). (2025). RNF180 weakened the lipid droplet formation and subsequent chemoresistance by destabilizing ACC1 and ACLY in esophageal cancer. Frontiers in Pharmacology.
Author(s). (2025). Chaetoglobosin A induces apoptosis in T-24 human bladder cancer cells through oxidative stress and MAPK/PI3K-AKTmTOR pathway. PeerJ.
Author(s). (2024). The promoting effects of Grin2d expression in tumorigenesis and the aggressiveness of esophageal cancer. Histology and Histopathology.
Author(s). (2024). The antitumor and sorafenib-resistant reversal effects of ursolic acid on hepatocellular carcinoma via targeting ING5. International Journal of Biological Sciences.
Author(s). (2024). The oncogenic roles of GPR176 in ovarian cancer: A molecular target for aggressiveness and gene therapy. Journal of Obstetrics and Gynaecology.